MicroRNA-761 inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by targeting mammalian target of rapamycin by 議곗젙�옒
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
MicroRNA-761 inhibits Angiotensin 
II-induced vascular smooth muscle cell 
proliferation and migration by 
targeting mammalian target of 
rapamycin
      
Jung Rae Cho
Department of Medicine
The Graduate School, Yonsei University
MicroRNA-761 inhibits Angiotensin 
II-induced vascular smooth muscle cell 
proliferation and migration by targeting 
mammalian target of rapamycin
Directed by Professor Namsik Chung
The Doctoral Dissertation
submitted to the Department of Medicine,
the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree 
of Doctor of Philosophy
Jung Rae Cho
June 2015
This certifies that the Doctoral 
Dissertation of Jung Rae Cho is 
approved.
정남식
------------------------------------
Thesis Supervisor: Namsik Chung
장양수
------------------------------------
Thesis Committee Member#1: Yangsoo Jang
황기철
------------------------------------
Thesis Committee Member#2: Ki-Chul Hwang
김경섭
------------------------------------
Thesis Committee Member#3: Kyung-Sup Kim
권영근
------------------------------------
Thesis Committee Member#4: Young-Geun Kwon
The Graduate School 
Yonsei University
June 2015
ACKNOWLEDGEMENTS
I owe my deepest gratitude to my supervisor, Professor 
Namsik Chung for inspiring and guiding me to the 
enlightening field of cardiology and cardiovascular 
intervention. His mentorship was paramount in providing key 
experiences in the process of cardiologic research. I am also 
grateful for his guidance which helped me pursue my 
academic career. I also would like to thank heartily Professor 
Ki-Chul Hwang who gave me an academic support throughout 
this study. His help was crucial in proceeding with this basic 
research study. I thank professors Yangsoo Jang, Kyung-Sup 
Kim and Young-Geun Kwon for providing the important and 
constructive comments and advices. Without the on-site help 
and hands-on experience of professor Seahyoung Lee in the 
laboratory procedures, conducting this research would have 
been impossible. I also appreciate his prompt and reliable help, 
and the experiences in problem-solving we have shared. 
Most importantly, I am very grateful to my wife, Ji-Yeoun
Lee for her love and emotional support throughout this study 
and during my difficult times. I dedicate this work to my 
parents who have always stood by my side. Lastly I would like 
to share this joy with my kids, Hyun-Woo and Hyun-Min.
<TABLE OF CONTENTS>
ABSTRACT ···································································1
I. INTRODUCTION···························································2
II. MATERIALS AND METHODS··········································4
1. Isolation and culture of rat aortic VSMCs ·····························4
2. Selection of miRNA targeting mTOR ··································4
3. MicroRNA transfection ·················································5
4. Cell proliferation assay··················································5
5. Real-time polymerase chain reaction (PCR)····························5
6. Reverse transcription polymerase chain reaction (RT-PCR) ···········6
7. Western Blot Analysis···················································6
8. Luciferase reporter assay ················································7
9. Migration assay··························································7
10. Wound healing assay ··················································7
11. Ring assay······························································8
11. Statistical analysis····················································8
III. RESULTS ·································································9
1. Ang II-induced rat aortic VSMC proliferation is mediated by 
mTOR····································································9
2. miR-761 directly targets mTOR and is down-regulated during 
AngII-induced VSMC proliferation ··································10
3. miR-761 suppresses Ang II-induced cell cycle progression and 
subsequent proliferation of VSMCs by inhibiting mTOR signaling 
pathway ··································································13
4. miR-761 inhibits migration in Ang II-stimulated VSMCs········15
IV. DISCUSSION ····························································17
V. CONCLUSION ···························································19
REFERENCES ·······························································20
ABSTRACT(IN KOREAN) 
LIST OF FIGURES
Figure 1. Ang II-induced VSMC proliferation is mediated by 
mTOR·····························································9
Figure 2. miR-761 targets mTOR and Ang II decreased 
miR-761 expression ············································12
Figure 3. miR-761 induces cell cycle arrest suppressing 
AngII-induced VSMC proliferation··························14
Figure 4. Effects of miR-761 on Ang II-stimulated VSMC 
migration ·························································16
1ABSTRACT
MicroRNA-761 inhibits Angiotensin II-induced vascular smooth muscle 
cell proliferation and migration by targeting mammalian target of 
rapamycin
Jung Rae Cho
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Namsik Chung)
Aberrant vascular smooth muscle cell (VSMC) proliferation and migration are a 
major pathological phenomenon in vascular disease characterized by intimal 
thickening. The important role of the mammalian target of rapamycin (mTOR) 
signaling in VSMC proliferation has been previously reported. Consequently, 
down-regulation of mTOR pathway may be an effective way of controlling 
excessive VSMC proliferation. Since microRNAs (miRNA) are newly 
emerging regulators of virtually all the biological processes including cellular 
proliferation, miRNAs targeting mTOR pathway may be able to suppress 
aberrant VSMC proliferation during pathologic vascular conditions. Thus, in the 
present study, we screened miRNAs targeting mTOR and identified miR-761 as 
a new mTOR targeting miRNA. Luciferase assay using luciferase vector 
containing 3’UTR of mTOR indicated that miR-761 directly targets mTOR 
mRNA leading to suppression of mTOR protein expression. Our data indicate 
that miR-761 expression decreases during angiotensin II (AngII)-induced 
proliferation of VSMCs, and exogenous miR-761 delivery effectively inhibit 
the AngII-induced VSMC proliferation. The results of migration assay 
demonstrated that down-regulation of mTOR using exogenous miR-761 
suppressed AngII-induced migration of VSMCs as well. Taken together, the 
present study provided evidence that miR-761 can be a potent anti-proliferative 
agent for VSMCs in vascular diseases such as atherosclerosis and restenosis, 
and warrants further studies to validate the effectiveness of miR-761 in vivo.
----------------------------------------------------------------------------------------
Keywords: Ang II, miR-761, mTOR, VSMC, proliferation
2MicroRNA-761 inhibits Angiotensin II-induced vascular smooth muscle 
cell proliferation and migration by targeting mammalian target of 
rapamycin
Jung Rae Cho
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Namsik Chung)
I. INTRODUCTION
Known as intimal hyperplasia, aberrant proliferation and migration of 
vascular smooth muscle cells (VSMCs) has been implicated in the development 
and progression of vascular diseases such as atherosclerosis and restenosis.1,2
Under physiologic conditions, the phenotype of VSMCs is predominantly 
contractile and quiescent. However, in response to vascular injury, various 
growth factors such as epidermal growth factor (EGF), fibroblast growth factor 
(FGF), platelet-derived growth factor (PDGF), and angiotensin II (AngII) are 
produced inducing VSMC proliferation.3 These growth factors activate 
corresponding receptors leading to initiation of signaling pathways, and one of 
the important pathways for VSMC proliferation is phosphoinositide 3-kinase 
(PI3K) signaling.4 The serine–threonine kinase Akt (also known as protein 
kinase B, PKB) is a key downstream component of PI3K pathway.5 Upon PI3K 
activation, Akt phosphorylates and inhibits the activity of glycogen synthase 
kinase-3 beta (GSK3β),6 which stimulates export and degradation of cyclin D,7
hence activation of PI3K signaling pathway stabilizes cyclin D and enhances 
3proliferation.8 Mammalian target of rapamycin (mTOR) is a critical regulator in 
cell proliferation that phosphorylated and activated by phosphatidylinositol 
3-kinase (PI3K)/AKT.9 Activated mTOR propagates signals through 
phosphorylation of downstream molecules p70 S6 kinase (P70S6K) and 
eukaryotic initiation factor 4E binding protein 1 (4EBP1).10 Such mTOR 
pathway -mediated SMC proliferation has been demonstrated in previous study 
used AngII as a proliferation inducing agent.11 Thus, considering the important 
role of mTOR pathway in SMC proliferation, disruption of mTOR pathway 
may be an effective way of preventing excessive SMC proliferation under 
pathologic conditions such as atherosclerosis or restenosis. MicroRNAs 
(miRNAs), small (~23 nucleotides) highly conserved non-coding RNAs, 
negatively regulate the expressions of target proteins by binding to 3’ 
untranslated region (3’UTR) in the target genes, subsequently degrading or 
suppressing translation of the target mRNAs.12 MicroRNAs regulate various 
biological functions including, apoptosis,13 cell cycle,14 differentiation,15 and 
proliferation.16 The aberrant changes of miRNAs in the vascular wall after 
angioplasty have been reported.17 Thus, in the present study, we examined the 
feasibility of suppressing AngII-induced excessive VSMC proliferation using 
exogenous miRNA targeting PI3K/AKT/mTOR pathway. In the present study, 
we screened miRNAs for targeting mTOR based on miRNA target prediction 
program, and the effect of selected miRNA on AngII-induced VSMC 
proliferation was examined further.
4II. MATERIALS AND METHODS
1. Isolation and culture of rat aortic VSMCs
All experimental procedures for animal studies were approved by the 
Committee for the Care and Use of Laboratory Animals, Yonsei University 
College of Medicine, and performed in accordance with the Committee’s 
guidelines and regulations for animal care. The thoracic aortas from 6- to 
8-week-old Sprague–Dawley rats were removed and transferred into serum-free 
DMEM (Dulbecco’s modified Eagle’s medium; Invitrogen, USA) containing 
100 units/ml penicillin and 100 mg/ml streptomycin. The connective tissues 
were removed and the aorta was transferred to a petri dish containing 5 ml of an 
enzyme dissociation mixture containing DMEM with 1 mg/ml collagenase type 
I (Sigma, USA) and 0.5 mg/ml elastase (USB Bioscience, USA), and incubated 
for 30 min at 37°C. The adventitia was stripped with forceps under a 
microscope. The aorta was transferred into a plastic tube containing 5 ml 
enzyme dissociation mixture and incubated for 2 hr at 37°C. The suspension 
was centrifuged (1500 rpm for 10 min), and the pellet was re-suspended with 
10% fetal bovine serum (FBS) containing DMEM with. Rat aortic SMCs were 
cultured in DMEM supplement with 10% FBS, 100 IU/ml penicillin and 100 
mg/ml streptomycin in 75 cm2 flasks at 37°C in a humidified atmosphere of 
95% air and 5% CO2 (Forma Scientific, USA).
2. Selection of miRNA targeting mTOR
First, miRNAs predicted to target mTOR were retrieved using a publicly 
available database (TargetScan, www.targetscan.org). The efficiency of 
miRNAs in down-regulating mTOR expression was empirically determined by 
5Western blot using mTOR specific antibodies.
3. MicroRNA transfection
Transfections of miRNA mimics were performed using siLentFect™ Lipid 
reagent (Life Science Research). Mature specific miRNA and miR-control 
(Genolution Pharmaceuticals, Inc., Korea) were used at a final concentration of 
100 nM. After 4 hr incubation in a CO2 incubator at 37°C, the medium was 
changed to 10% FBS containing DMEM.
4. Cell proliferation assay
Rat aortic VSMCs were plated in 96-well plates at 5x103 per well. Cells were 
transfected with miRNA mimics 24 hr prior to AngII (Sigma) exposure for 48 
hr. After treatment, 10ul of the WST-8 
[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetra
zolium, monosodium salt] solution (Dojindo, Japan) was added to each well and 
incubated at 37°C for 2 hr to allow formation of WST-8 formazan. The 
absorbance of a water soluble formazan dye was measured at 450 nm using a 
microplate reader (Molecular Devices, USA). Experiments were performed in 
triplicate.
5. Real-time polymerase chain reaction (PCR)
Total RNA was isolated with TRIzol® Reagent (Life Technologies, USA). In 
brief, 100 ng purified total RNA was used for reverse transcription (Taqman® 
MicroRNA Reverse Transcriptase Kit, Applied Biosystems, USA) in 
combination with Taqman® MicroRNA Assays for quantification of specific 
miRNAs and U6 control transcripts, according to the manufacturer’s conditions. 
6The threshold cycle (Ct) of each target gene was automatically defined, located 
in the linear amplification phase of the PCR, and normalized to control U6 (ΔCt 
value).
6. Reverse transcription polymerase chain reaction (RT-PCR)
Cellular total RNA was isolated with TRIzol® Reagent (Life Technologies, 
USA). Single-stranded cDNA was synthesized from total RNA using a reverse 
transcription system (Promega, USA) according to the manufacturer’s protocol. 
The primer sequences were as follows: GAPDH, sense: 5’ – GGT GAT GCT 
GAG TA - 3’ and antisense: 5’ –GGA TGC AGG GAT GAT GTT CT– 3’ 
(369bp); mTOR, sense: 5’ – TTG AGG TTG CTA TGA CCA GAG AGA A–
3’ and antisense: 5’ –TTA CCA GAA AGG ACA CCA GCC AAT G– 3’ 
(540bp).  
7. Western Blot Analysis
VSMCs cultured in 60-mm dishes were treated with or without miRNA mimics 
that were predicted to target mTOR and stimulated with AngII. Proteins were 
separated in a 10% SDS-polyacrylamide gel and transferred to PVDF 
membrane (Millipore, USA). After blocking the membrane with TBS-T 
(TBS-tween 20, 0.1% tween 20) containing 5% (w/v) non-fat dried skimmed 
milk powder for 1 hr at room temperature, membranes were washed twice with 
TBS-T and incubated with primary antibodies for 1 hr at room temperature or 
overnight at 4°C. The membrane was washed three times with TBS-T for 5 min 
and incubated with HRP (horseradish peroxidase)-conjugated secondary 
antibody for 1 hr at room temperature. After extensive washing, the bands were 
detected using ECLⓇ (enhanced chemiluminescence) reagent (AbClon, 
Republic of Korea). The band intensities were detected using a Photo-Image 
7System (Molecular Dynamics, Canada). The primary antibodies were from Cell 
Signaling (mTOR:2972, p-mTOR:2971, P70S6K:9202, p-P70S6K:9206, 
4EBP1:9452, p-4EBP1:9459, cyclin D1:9262), except the β-actin (Abcam, 
ab8227).
8. Luciferase reporter assay
We synthesized the 3′-UTR of rat mTOR containing the predicted binding sites 
for corresponding miRNA. The 3’-UTR fragments were then cloned into the 
pmirGLO vector (pmTOR-3UTR). HeLa cell was plated at 1×105 in 12 well 
plates. After 24 hr, the cells were co-transfected with pmTOR-3UTR vector, 
negative control miRNA mimic (NC), and miR-761 using siLentFect™ Lipid 
reagent. The Renilla luciferase was used for normalization. Luciferase activity 
was measured by the Dual Luciferase assay (Promega, USA) according to the 
manufacturer’s instructions after 24 hr. Each assay was repeated three times.
9. Migration assay
VSMCs (8 × 103 cells) were seeded onto the upper chamber of a Transwell 
filter with 8 μm pores (Costar Corning, USA) coated with 10 μg/ml fibronectin. 
The cells were deprived of serum for 24 hr, and AngII-containing stimulating 
medium (50nM) was added to the lower chamber. Transwell chambers were 
incubated at 37°C for 24 hr. After incubation, the cells migrated through the 
pores of the filter were stained with 0.25% crystal violet. Non-migrating cells 
on the upper side of the filter were removed with cotton swabs.
10. Wound healing assay
VSMCs were plated at a density of 8 × 104 cells/well in six-well plates. After 
8the cells had reached 90% confluence, cells were deprived of serum for 24 hr. 
After incubation, wounds were produced by scratching with 200 μL pipette tips. 
The leading edge of the wounds was marked as a baseline. The medium was 
replaced with or without serum-deprived medium-containing AngII (50 nM), 
and the cells were incubated for 0 and 48 hr. Images were captured using an 
Axiovert 40C inverted microscope (Carl Zeiss, Germany) equipped with a 
Powershot A640 digital camera (Canon, Japan).
11. Ring assay
The rat aorta was isolated and cleaned of perivascular adipose tissue. The 
isolated rat aortas were cut into segments of 1 mm long aortic rings that were 
placed in Matrigel (BD Biosciences, USA). The aorta rings were transfected 
with miRNA mimics prior to treatment with media containing AngII. Over the 
next 7 days, the aorta rings were monitored for the outgrowth of VSMCs using 
microscope once per day.
12. Statistical analysis
Quantitative data were expressed as the means ± SEM. For statistical analysis, 
one-way ANOVA with Bonferroni correction was performed using the 
OriginPro 8 SR4 software (ver. 8.0951, OriginLab Corporation, Northampton, 
MA, USA) if there were more than 3 groups. For two group comparison, 
student’s t-test was used. A p value of less than 0.05 was considered to be 
statistically significant.
9III. RESULTS
1. AngII-induced rat aortic VSMC proliferation is mediated by mTOR
AngII significantly increased VSMC proliferation at the concentrations of 50 
nM or higher (Fig. 1A). However, when the cells were pretreated with 
rapamycin, a potent inhibitor of mTOR,18 AngII-induced VSMC proliferation 
was suppressed indicating that mTOR was involved in the AngII-induced 
proliferation of VSMCs (Fig. 1B). Since 50nM (or higher) AngII induced 
VSMC proliferation, 50nM of AngII was used to stimulate VSMC proliferation 
for further experiments.
Fig. 1. AngII-induced VSMC proliferation is mediated by mTOR. (A) Relative VSMC 
proliferation with increasing concentrations of AngII (10~200nM) was measured. *P <0.05 (B) 
The effect of rapamycin (mTOR inhibitor) on AngII-induced VSMC proliferation was measured., 
**P<0.01, #p<0.05 vs. control.
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2. miR-761 directly targets mTOR and is down-regulated during 
AngII-induced VSMC proliferation
We have hypothesized that AngII-induced proliferation of VSMCs may 
involve down-regulation of mTOR-targeting miRNAs, leading to increased 
mTOR activity. To test the hypothesis, first, we have selected 16 miRNAs 
based on miRNA database (www.TargetScan.org) (Table. 1).
Table. 1. miRNAs targeting mTOR from miRNA database (www.TargetScan.org)
miRNA
Position
(of mTOR 3’UTR)
Sequence (miRNA)
Aggregate
(Pct)
miR-96 809 - 815 3' - UCGUUUUUACACGAUCACGGUUU - 5’ 0.79
let-7a 420 - 426 3' - UUGAUAUGUUGGAUGAUGGAGU - 5’ 0.73
let-7b 420 - 426 3' - UUGGUGUGUUGGAUGAUGGAGU - 5’ 0.73
let-7c 420 – 426 3' - UUGGUAUGUUGGAUGAUGGAGU - 5’ 0.73
let-7d 420 - 426 3' - UUGAUACGUUGGAUGAUGGAGA - 5’ 0.73
miR-98 420 - 426 3' - UUGUUAUGUUGAAUGAUGGAGU - 5’ 0.73
miR-144 127 - 133 3' - UCAUGUAGUAGAUAUGACAU - 5’ 0.31
miR-101b 127 - 133 3' - AAGUCGAUAGUGUCAUGACAU - 5’ 0.31
miR-7 488 - 495 3' - UGUUGUUUUAGUGAUCAGAAGGU - 5’ 0.14
miR-150 259 - 266 3' - GUGACCAUGUUCCCAACCCUCU - 5’ <0.1
miR-223 280 - 286 3' - CCCCAUAAACUGUUUGACUGU - 5’ <0.1
miR-15b 617 - 623 3' - ACAUUUGGUACUACACGACGAU - 5’ <0.1
miR-761 615 – 621 3' - ACACAGUCAAAGUGGGACGACG - 5’ <0.1
miR-214 615 – 621 3' - GACGGACAGACACGGACGACA - 5’ <0.1
miR-143 21 - 27 3' - ACUCGAUGUCACGAAGUAGAGU - 5’ <0.1
miR-99a 294 - 300 3' - GUGUUCUAGCCUAGAUGCCCAA - 5’ <0.1
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Next, we transfected rat VSMCs with selected miRNAs, and then evaluated 
mTOR expression using Western blot (Fig. 2A). Four miRNAs 
(miR-143/150/214/761) significantly repressed mTOR expression. However, 
three of them (miR-143/150/214) induced significant cell death (data not 
shown), thus consequently excluded from further experiments. The expression 
of miR-761 was significantly decreased as the VSMCs proliferated in response 
to AngII treatment (Fig. 2B).
For luciferase assay, the 3’-UTR of mTOR was cloned into a pmirGLO vector 
using xhoI and xbaI endonuclease site to produce a pmTOR-3UTR vector. 
HeLa cells were transiently transfected with the pmTOR-3UTR vector (or 
pmirGLO control vector), in combination with miR-761 mimics or negative 
control mimics (scrambled miRNA; N.C.). Transfection with miR-761 
significantly decreased luciferase activity in pmTOR-3UTR group, while it had 
no significant effect on pmirGLO control vector transfected group (Fig. 2C). 
Although mRNA expression of mTOR was not changed by miR-761 
transfection (Fig. 2D), mTOR protein expression was decreased by miR-761 
transfection (Fig. 2E), suggesting the inhibitory mechanism of miR-761 on 
mTOR expression was to disrupt translation of mTOR from mRNA rather than 
degradation of mRNA itself.
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Fig. 2. miR-761 targets mTOR and AngII decreased miR-761 expression. (A) VSMCs 
transfected with candidate mTOR-targeting miRNAs and the expressions of mTOR protein was 
determined by Western blot. β-actin served as a loading control. *P<0.001 and **P<0.01 (B)
Expression of miR-761 was detected by real time PCR in AngII stimulated VSMCs. #p<0.05. (C) 
miR-761 targeting 3’UTR of mTOR was verified by using luciferase reporter assay. Luciferase 
vector containing 3’UTR of mTOR was constructed and the resultant vector was co-transfected 
into HeLa cells with negative control (scrambled miRNA) or miR-761. **P<0.01. (D) The 
mRNA level of mTOR was analyzed by RT-PCR. GAPDH was used as a control. (E) VSMCs 
transfected with N.C. or miR-761 mimic were stimulated with Ang-II (50 nM) and analyzed for 
the mTOR protein level by western blot. β-actin was used as a control.
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3. miR-761 suppresses AngII-induced cell cycle progression and subsequent 
proliferation of VSMCs by inhibiting mTOR signaling pathway
Although the percentage of cells in S phage of rapamycin-treated cells was 
lower than that of miR-761-treated cells, the percentage of cells in S phase of 
miR-761-treated cells was still lower than that of AngII-stimulated cells (Fig. 
3A). The results of cell viability assay also indicated that transfection of 
miR-761 suppressed AngII-induced proliferation in a dose-dependent manner 
(Fig. 3B). Such anti-proliferative effect of miR-761 was further demonstrated 
by immunocyto-chemical staining of Ki-67, a proliferating cell marker.19 The 
expression of Ki-67 was significantly decreased in miR-761-transfected 
VSMCs compared to AngII-stimulated cells (Fig. 3C). Additionally, we 
examined the phosphorylation status of p70S6k and 4EBP1 that is known to be 
regulated by mTOR.20 The results of Western blot indicated that the 
phosphorylation of p70S6k and 4EBP1 were decreased in the miR-761 
transfected group. These data suggested that exogenous miR-761 delivery 
decreased biological activity of mTOR, subsequently suppressing activation of 
mTOR/p70S6K/4EBP1 signal pathway (Fig. 3D).  
14
Fig. 3. miR-761 induces cell cycle arrest suppressing AngII-induced VSMC proliferation. (A) 
VSMCs were stimulated with 50nM of AngII with or without miR-761 or mTOR inhibitor 
(rapamycin) pretreatment. Cell cycle analysis was performed by using FACS. (B) The effect of 
miR-761 on 50nM AngII-treated VSMC proliferation. Relative proliferation was measured. 
**P<0.01. (C) Representative images of Ki-67 (Green) and DAPI (blue) staining. Scale bar (white 
bar) represents 100 μm. **P<0.01. (D) Phosphorylation status of downstream effectors of mTOR 
signaling.
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4. miR-761 inhibits migration in Ang II-stimulated VSMCs
Migration of VSMC under pathologic condition has been reported to 
contribute to development of vascular diseases, including atherosclerosis and 
post-angioplasty restenosis.21 AngII treatment significantly increased the 
number of migrated cells, and this increase was significantly suppressed by both 
miR-761 and rapamycin transfected VSMCs than Ang II-stimulated cells. 
MiR-761 also inhibited migration of Ang II-stimulated VSMCs (Figure. 4A). In 
wound healing assay, the distance between wound edges were shortest in the 
AngII-stimulated group, while the miR-761-treated group and the 
rapamycin-treated group showed longer distance compared to the AngII-treated 
group (Fig. 4B). The number of VSMC sprouting from the aortic rings of 
miR-761-treated group was lower compared to the AngII-treated group (Fig. 
4C), indicating that miR-761 suppressed not only VSMC proliferation, but also 
cell migration.
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Fig. 4. Effects of miR-761 on AngII-stimulated VSMC migration. (A) Effects of miR-761 on 
VSMCs migration. Transwell migration assay was used to estimate the migration of VSMCs. To 
induce cell migration, the cells were incubated with 50 nM of AngII for 18 hr. **P<0.01. (B) 
Representative images of wound closing. VSMC migration was induced by 50nM of AngII 
migration. The distance between wound edges was measured. *P <0.001, **P<0.01. (C) Rat 
aortic rings (1 mm) were embedded and cultured in Matrigel in the presence of 50 nM of AngII 
with or without miR-761 transfection or rapamycin treatment. The images were taken on 7th day 
of stimulation.
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IV. DISCUSSION
Accumulating evidence suggests that miRNAs play important roles in 
regulating VSMC proliferation. For example, miRNA-21 has been reported to 
increase VSMC proliferation after vascular injury by targeting phosphatase and 
tensin homolog (PTEN).17 Furthermore, miR-221 and -222 also increased 
VSMC proliferation by targeting p27kip1 and p57kip2, respectively.22 On the 
other hand, miR-26a, -143, and -145 have been demonstrated to decrease 
VSMC proliferation.23,24 Additionally, involvement of miRNAs in phenotypic 
switch of VSMCs and their proliferation during neointima formation has been 
demonstrated.25 These studies strongly suggest that miRNA-dependent 
regulation of VSMC proliferation and migration is an important component of 
vascular biology, as well as of development and progression of vascular 
diseases.
The correlation between AngII and vascular diseases such as atherosclerosis 
has long been recognized.26 Furthermore, a previous study reported that AngII 
induced proliferation and migration of VSMCs by activating mTOR signal 
pathway,11 indicating inhibition of mTOR pathway may be an effective way of 
suppressing excessive VSMC proliferation and migration under pathologic 
conditions such as atherosclerosis. In the present study, we identified a new 
miRNA, namely miR-761, which inhibits mTOR expression by binding to its 3’ 
UTR. Our data showed that exogenous miR-761 delivery can effectively 
suppress the AngII-induced VSMC proliferation and migration. It has been 
reported that G1 cell cycle progression is regulated by PI3K/Akt/mTOR/p70S6k 
signaling.27 Thus, disruption of this signaling pathway can lead to cell cycle 
arrest, and exogenous miR-761 produced such result in the present study. 
To date, only few papers have been published regarding the role of miR-761 
in biological systems. In fact, as of 2014 Dec, PubMed search using miR-761 as 
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a key word resulted only 2 research articles. One study implicated miR-761 in 
controlling nervous system development,28 and the other study indicated that 
miR-761 acts as an anti-apoptotic molecule targeting mitochondrial fission 
factor (MFF).29 Thus, this study is the first in vitro study proved the concept that 
delivery of exogenous miR-761 can be an effective anti-proliferative therapy by 
down-regulating mTOR signaling pathway. However, this anti-proliferative 
effect of miR-761 has to be further validated using an in vivo model, and there 
are few points need to be considered prior to any in vivo study.
One of the obvious limitations of the present study is that the 
anti-proliferative effect of miR-761 was examined in only one type of cells, 
VSMCs. In other words, the effect of miR-761 may not be VSMC specific 
when it is delivered in vivo. For example, if miR-761 is used to suppress 
neointima formation after balloon injury, miR-761 can be delivered via 
intravenous injection. However, this systemic delivery of miR-761 can be 
problematic because indiscriminate delivery of miR-761 can result in unwanted 
suppression of vascular endothelial cell (EC) growth as well. Since rapid 
regrowth of EC, called re-endothelialization, has been considered important in 
preventing intimal thickening as well as vascular thrombosis,30,31 preventing 
proliferation of EC should not be occur. Considering such possibility, local 
delivery rather than systemic delivery seems to be logical approach because 
local delivery immediately after the balloon injury (denudation of existing 
endothelium) can directly target the VSMCs exposed rather than targeting the 
neighboring intact ECs. Additionally, a proven, effective mean of miRNA 
delivery should be ready prior to conducting an in vivo study. Consequently, 
further studies that can address these issues are warranted.
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V. CONCLUSION
The present study, for the first time, provided evidence that miR-761 
suppresses VSMC proliferation and migration through repression of mTOR 
expression and subsequent down-regulation of p70S6K/4EBP1. With further in 
vivo validation and optimization of delivery system, exogenous miR-761 can be 
a potent therapeutic agent for the treatment of restenosis and atherosclerosis.
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ABSTRACT(IN KOREAN)
mTOR 경로에 대한 miR-761의 안지오텐신-II 매개성
혈관평활근세포의 증식과 이동의 억제효과
<지도교수 정 남 식>
연세대학교 대학원 의학과
조  정  래
비정상적인 혈관 평활근세포의 증식과 이동은 내막비후가 특징적인
혈관질환의 주된 병태 현상이다. 혈관평활근세포의 증식에서 mTOR 
신호전달체계의 중요성은 잘 알려져 있다. 따라서, mTOR 경로의
하향조절 (down-regulation)은 과도한 혈관평활근세포의 증식을
조절하는 효과적인 방법이 될 수 있다. MicroRNA (miRNA) 가
세포증식을 포함하는 다양한 생물학적 과정을 제어한다고 알려져
있고, 따라서 mTOR 경로를 겨냥하는 miRNA 는 병적인 혈관상태에서
비정상적인 혈관평활근세포의 증식을 억제할 수 있겠다. 본
연구에서는 mTOR 를 겨냥하는 miRNA 들을 선별하여 이중
miR-761를 연구에 이용하였다. 백서의 대동맥 평활근세포를 분리하고, 
여기에 miR-761 를 투여하여 실험을 진행하였다. 본 연구에서는
miR-761이 혈관평활근세포 증식과 이동에서 중요한 역할을 하고
있음을 증명하였다. 첫째, mTOR 의 3’UTR을 함유하는 luciferase vector 
를 사용한 luciferase assay 결과에서, miR-761 이 mTOR mRNA 를 직접
겨냥하여 mTOR 단백의 발현을 억제시켰다. 둘째, 안지오텐신-II 에
의해 유발된 혈관평활근세포의 증식시 miR-761의 발현이 감소되고, 
exogenous miR-761 이 이러한 세포증식을 효과적으로 억제함을 보였다. 
셋째, migration assay 에서도 miR-761 의 투여로 인한 mTOR 의
하향조절이 안지오텐신-II 에 의해 유발된 혈관평활근세포의 증식을
억제하였다. 위 결과들은 토대로 miR-761이 동맥경화 또는
혈관재협착과 같은 혈관질환에서 혈관평활근세포의 강력한
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항증식제로써 가능성을 확인하였으며, 생체내 (in vivo)에서의
miR-761의 유용성을 검증하는 후속 연구가 기대될 수 있겠다.
----------------------------------------------------------------------------------------
핵심되는 말: 안지오텐신-II, miR-761, mTOR, 혈관평활근세포, 증식
